The GOLD criteria are a set of diagnostic and management guidelines published by the Global Initiative for Chronic Obstructive Lung Disease, an international body that has shaped how doctors identify, classify, and treat COPD since its first report in 2001. At their core, the criteria define COPD as persistent airflow limitation confirmed by spirometry, specifically a post-bronchodilator ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) that falls below 0.70. But the framework goes well beyond that single number, layering in symptom scores, exacerbation history, and biomarkers to guide personalized treatment decisions.
How the Spirometry Diagnosis Works
Spirometry is a breathing test where you exhale as hard and as fast as possible into a tube. Two measurements matter most: FEV1, the volume of air you can push out in the first second, and FVC, the total volume you can exhale. The ratio between them tells clinicians how obstructed your airways are. In healthy lungs, you can blow out most of your air quickly, so the ratio stays well above 0.70. When the ratio drops below that threshold after using a bronchodilator (an inhaled medication that relaxes airway muscles), the GOLD criteria consider the airflow limitation confirmed.
Once obstruction is established, the severity is graded on a four-tier scale based on how far FEV1 has fallen relative to predicted values for someone of your age, sex, and height. GOLD 1 means FEV1 is still at or above 80% of predicted, which is considered mild. GOLD 2 spans 50% to just under 80% (moderate). GOLD 3 covers 30% to just under 50% (severe), and GOLD 4 means FEV1 has dropped below 30% of predicted, which is very severe.1PubMed Central. FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease These stages describe the degree of obstruction but do not, on their own, dictate treatment. A person with GOLD 2 obstruction who rarely has flare-ups and feels relatively well needs a different plan from someone at GOLD 2 who is frequently hospitalized.
The Fixed Ratio Debate
The 0.70 cutoff is convenient, but it has been controversial for decades. The ratio of FEV1 to FVC naturally declines with age, meaning an otherwise healthy 75-year-old might blow a ratio just under 0.70 without having any lung disease at all. Data from the multinational BOLD study showed that using this fixed ratio led to age-related increases in apparent COPD rates among healthy never-smokers, an increase that largely disappeared when researchers instead used the lower limit of normal, a statistically derived threshold adjusted for age, sex, and height.2European Respiratory Journal. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study
That finding raised the worry that the fixed ratio overdiagnoses older adults. A Canadian cohort study went further, finding that patients flagged as obstructed by the fixed ratio alone, but not by the lower limit of normal, had only small, statistically nonsignificant increases in adverse outcomes. Patients who met both criteria showed much larger, significant increases.3The Annals of Family Medicine. Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort A systematic review reconciling the two approaches suggested that when the two criteria disagree, an alternative diagnosis should be considered, particularly in older adults with milder obstruction, for whom the lower limit of normal seems more accurate. The fixed ratio, however, appears to perform better in people with more severe obstruction.4PubMed. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review
Despite these limitations, GOLD has kept the 0.70 fixed ratio as its primary diagnostic threshold. The reasoning is largely practical: the fixed ratio is simpler, does not require reference equations that vary between populations, and is easy to apply in primary care settings worldwide. Still, clinicians are increasingly aware that the diagnosis in a borderline older patient deserves extra scrutiny before labeling someone with a chronic disease and starting long-term inhalers.
Groups A, B, and E
Spirometric severity alone turned out to be a poor guide for treatment. Two patients in GOLD stage 2 can have wildly different daily lives, one getting by with minimal breathlessness and the other struggling to walk across a room and bouncing in and out of the hospital with flare-ups. Starting with its 2011 revision, GOLD introduced a symptom-and-risk assessment that classifies patients into groups based on how much trouble they experience day to day and how often they have exacerbations.
The original grouping scheme divided patients into four categories, A through D, using two axes: symptom burden (low versus high) and exacerbation risk (low versus high). This created a matrix where Group A had few symptoms and few exacerbations, Group D had heavy symptoms and frequent exacerbations, and Groups B and C occupied intermediate spots. In practice, though, Group C was lightly populated and the distinction between C and D confused clinicians. Recent GOLD updates collapsed the two high-exacerbation groups into a single Group E, yielding three groups. Group A includes patients with low symptoms (an mMRC breathlessness score of 0 or 1, or a CAT score below 10) and no more than one moderate exacerbation in the past year. Group B has higher symptoms but similarly low exacerbation risk. Group E captures anyone with two or more moderate exacerbations or at least one exacerbation leading to hospitalization in the past year, regardless of symptom burden.5Archivos de BronconeumologÃa. A Novel Figure and Algorithm for the Gold ABE Classification The creation of Group E signals that frequent flare-ups are the most critical driver of treatment escalation.
Symptom Scores and Why Both Matter
GOLD uses two questionnaires to measure symptom burden. The mMRC dyspnea scale is a five-point self-rating of breathlessness during daily activities, from “I only get breathless with strenuous exercise” (grade 0) to “I am too breathless to leave the house” (grade 4). The COPD Assessment Test, or CAT, is an eight-item questionnaire covering cough, phlegm, chest tightness, breathlessness, activity limitation, confidence, sleep, and energy. A score of 10 or above on the CAT, or 2 or above on the mMRC, is the threshold for “more symptomatic.”
These two tools correlate with each other, but they are not interchangeable. One study found that while the overall correlation between CAT and mMRC was strong, a meaningful number of patients scored as low-symptom on one tool and high-symptom on the other, leading to different group assignments depending on which questionnaire was used.6PubMed Central. How to Utilize CAT and mMRC Scores to Assess Symptom Status of Patients with COPD in Clinical Practice? The mismatch happens because the mMRC captures only breathlessness, while the CAT also picks up impacts like poor sleep, low energy, and reduced confidence. A comparative study found that the CAT was better at capturing certain comorbidities and intensive care admissions, while the mMRC performed slightly better at distinguishing patients who ended up in emergency rooms or needed hospitalization.7PubMed. Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients Some researchers recommend using both tools together when assigning a patient to a low-symptom group, accepting a high score on either one as sufficient to push a patient into the more-symptomatic category, to avoid under-classifying someone who is truly struggling.
How GOLD Groups Guide Treatment
The group assignment steers initial pharmacotherapy. Group A patients typically start with a single short- or long-acting bronchodilator as needed. Group B patients are usually started on a long-acting bronchodilator, either a long-acting muscarinic antagonist or a long-acting beta-agonist, with combination dual bronchodilator therapy recommended when symptoms persist. Evidence from a systematic review and meta-analysis supports dual bronchodilator therapy over monotherapy in symptomatic patients, showing reduced exacerbation risk and fewer hospitalizations.8Annals of the American Thoracic Society. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline
Group E patients, who by definition have frequent exacerbations, are treated more aggressively from the start. Dual bronchodilator therapy is the foundation, but the decision to add an inhaled corticosteroid depends on blood eosinophil levels, a biomarker GOLD now formally incorporates into its treatment algorithm.
Blood Eosinophils and Inhaled Corticosteroids
Not every COPD patient benefits from inhaled corticosteroids, and one of the more meaningful shifts in recent GOLD updates is the use of blood eosinophil counts to predict who will respond. GOLD considers a count below 100 cells per microliter a marker of poor responsiveness to inhaled corticosteroids.9PubMed Central. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort A count above about 300 cells per microliter suggests a higher likelihood of benefit, especially in patients with frequent exacerbations.
The science behind this threshold comes from trials like one in which patients with blood eosinophils at or above 2% of white blood cells experienced a meaningful slowing in lung-function decline when treated with an inhaled corticosteroid versus a placebo. Patients below that 2% mark showed no such benefit.10PubMed. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD The practical takeaway is that doctors should not reflexively add steroids to every COPD regimen. In patients with low eosinophils, the risks of inhaled corticosteroids, including pneumonia, can outweigh the benefits. In patients with higher eosinophils and ongoing exacerbations, adding them makes more sense. This biomarker-guided approach represents a shift toward personalized treatment rather than a one-size-fits-all escalation ladder.
Newer Targeted Therapies
For patients whose eosinophilic inflammation persists despite triple therapy (a combination of two bronchodilators plus an inhaled corticosteroid), biologic medications are entering the picture. Dupilumab and mepolizumab, drugs already approved for severe asthma, have shown improved outcomes in eosinophilic COPD.11PubMed Central. Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies Phosphodiesterase inhibitors represent another avenue. Roflumilast, an oral medication, reduces exacerbations in patients with chronic bronchitis symptoms and a history of frequent flare-ups. Ensifentrine, a newer inhaled dual-action phosphodiesterase inhibitor, combines bronchodilator and anti-inflammatory effects and is expanding available options.
Biologics are not for every COPD patient. They are expensive, require ongoing injections, and are currently relevant mainly for the subset with elevated eosinophils who keep flaring despite maximal inhaled therapy. But their arrival means that the treatable traits framework GOLD now promotes, matching treatments to specific inflammatory profiles rather than just lung function numbers, has real drugs behind it.
Pre-COPD and the PRISm Pattern
GOLD has increasingly recognized that COPD does not start the day spirometry first crosses the 0.70 threshold. A pattern called preserved ratio impaired spirometry, or PRISm, describes people whose FEV1-to-FVC ratio is still above 0.70 but whose FEV1 is already below 80% of predicted. In other words, both airways and overall lung volume are reduced proportionally, so the ratio looks normal, but total lung function is already impaired. PRISm is more commonly observed in people with higher body mass, women, and current smokers, and it is frequently accompanied by metabolic and cardiovascular conditions.12PubMed Central. Preserved ratio impaired spirometry: clinical, imaging and artificial intelligence perspective
PRISm matters because it is not a stable state. Some people with PRISm improve over time, but a substantial fraction progress to full airflow obstruction meeting the COPD definition. A large study found that PRISm was associated with transition to COPD-pattern obstruction within a decade, and this association held regardless of smoking status, including in people who had never smoked.13PubMed Central. Importance of Preserved Ratio Impaired Spirometry as a Risk Factor for Development of COPD, Also in Those Who Do Not Smoke Predictive modeling work suggests that older age, worse baseline lung function, breathlessness, respiratory complications, and elevated red blood cell counts increase the risk of PRISm progressing to COPD.14Scientific Reports. Nomogram to predict progression from preserved ratio impaired spirometry to chronic obstructive pulmonary disease GOLD now considers PRISm a form of pre-COPD, with the implication that early intervention, such as aggressive smoking cessation and monitoring, could potentially slow the trajectory before full obstruction develops.
Beyond Spirometry and the BODE Index
One recurring criticism of the GOLD framework is that it still revolves heavily around a single breathing test. FEV1 tells you how obstructed the airways are, but it says surprisingly little about how a patient actually functions or how long they will live. The BODE index was developed to address this gap by combining four dimensions: body mass index, degree of obstruction (FEV1), dyspnea (breathlessness), and exercise capacity measured by a six-minute walk test. Studies have found that the BODE index outperforms FEV1 alone in predicting hospitalizations and mortality.15PubMed Central. Using the BODE Index and Comorbidities to Predict Health Utilization Resources in Chronic Obstructive Pulmonary Disease
Head-to-head comparisons between classification systems show that the GOLD ABCD grouping does predict overall mortality, but the BODE index tends to outperform it. One study found that the BODE index showed a higher area under the curve for mortality prediction than GOLD’s ABCD system.16PubMed. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE Despite this, the BODE index has not been formally integrated into GOLD’s treatment algorithm, partly because it requires a supervised six-minute walk test, which is harder to administer in a busy primary care clinic than a spirometry reading and a questionnaire. Still, pulmonologists frequently use the BODE index alongside GOLD staging to get a fuller picture, especially when making decisions about referral for lung transplant evaluation or surgical interventions.
Non-Pharmacological Cornerstones
Medications get the most attention, but GOLD is clear that non-drug measures are the foundation of treatment at every stage. Smoking cessation is the single most effective intervention for slowing lung function decline. Vaccination against influenza, pneumococcal disease, COVID-19, and respiratory syncytial virus reduces the risk of exacerbations triggered by infections. Pulmonary rehabilitation, which combines supervised exercise training, education, and behavioral support, improves exercise tolerance, reduces breathlessness, and lowers hospital admissions.17Journal of Chronic Obstructive Pulmonary Disease. GOLD Stage and Treatment in COPD: A 500 Patient Point Prevalence Study
For patients with severe emphysema and significant hyperinflation who are not adequately controlled on optimal medical therapy, lung volume reduction, either through surgery or less invasive bronchoscopic procedures using valves, is an option that GOLD recognizes in selected cases.18European Respiratory Journal. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary Long-term oxygen therapy remains indicated for patients with severely low blood oxygen levels, a criterion that has remained stable across GOLD revisions.
How Well Doctors Actually Follow the Guidelines
The gap between what GOLD recommends and what happens in real clinics is wide. In a Swiss cohort study of over 1,100 primary care visits for COPD patients, treatment matched GOLD recommendations in only about two-thirds of visits. The biggest problems were overtreatment of mild disease: half of Group A visits involved prescription of two long-acting bronchodilators when one would have sufficed, and about a quarter of Group B visits included an inhaled corticosteroid that guidelines did not recommend.19PubMed Central. Adherence to the GOLD Guidelines in Primary Care: Data from the Swiss COPD Cohort
On the other end, underuse of spirometry is a persistent problem. Surveys of primary care providers have found that fewer than a quarter report consistently using spirometry to guide management, and referral rates to pulmonary rehabilitation are even lower, around 5% in one study for patients whose lung function would warrant it.20Respiratory Medicine. Barriers to adherence to COPD guidelines among primary care providers Time pressure and low confidence in interpreting spirometry results were among the biggest barriers.21PubMed Central. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians The result is a pattern where mild patients are often overtreated with expensive combination inhalers they do not need, while sicker patients miss out on pulmonary rehabilitation and structured follow-up that would genuinely improve their lives.
COPD Beyond Smoking
GOLD has broadened its lens on what causes COPD. While cigarette smoking remains the leading risk factor globally, the most recent updates explicitly recognize multiple “etiotypes,” different causal pathways that lead to the same airflow limitation. These include genetically determined COPD (such as alpha-1 antitrypsin deficiency, a rare inherited condition), COPD caused by abnormal lung development (for instance, from premature birth), and environmental COPD arising from exposure to biomass fuels or air pollution rather than cigarettes. This recognition matters because a nonsmoker whose lungs were damaged by years of cooking over indoor biomass fires has the same spirometric picture as a lifelong smoker but may have different inflammatory profiles and different responses to treatment. As the field shifts toward treatable traits rather than a single disease label, GOLD’s expanding etiotype framework is pushing clinicians to ask not just “does this person have COPD?” but “what kind, and why?”
When COPD Meets Heart Failure
COPD rarely exists in isolation. Among the most clinically challenging overlaps is the coexistence of COPD and heart failure, conditions that share risk factors (smoking, age, systemic inflammation) and produce overlapping symptoms like breathlessness, exercise intolerance, and fatigue. Epidemiological data suggest that up to about a third of heart failure patients also have COPD.22PubMed Central. The Complex Relationship Between Heart Failure and Chronic Obstructive Pulmonary Disease: A Comprehensive Review Diagnosing one condition in the presence of the other is notoriously difficult: chest X-rays, ECGs, and even blood biomarkers can be distorted by the coexisting disease process.23PubMed Central. The Coexistence of Chronic Obstructive Pulmonary Disease and Heart Failure
A prospective study in specialized clinics found that roughly a quarter of diagnosed COPD patients had unrecognized heart failure, and a similar proportion of heart failure patients had unrecognized COPD. Those with the overlap had higher exacerbation rates, suggesting that the undiagnosed condition was contributing to flare-ups attributed to the diagnosed one.24PubMed. Personalizing the approach for the diagnosis of patients with concomitant Chronic Obstructive Pulmonary Disease and Heart failure This is the kind of gap that GOLD’s spirometry-centered framework struggles with: a breathing test tells you the airways are obstructed, but it cannot tell you whether the breathlessness sitting in front of you is driven by the lungs, the heart, or both. GOLD increasingly acknowledges that comprehensive evaluation, including echocardiography and cardiovascular risk assessment, should complement spirometry in COPD management, especially for patients who remain symptomatic despite appropriate inhaler therapy.
Disease Activity as a Newer Target
The most recent GOLD updates have introduced the concept of “disease activity” as a formal therapeutic target, moving the framework further from a static classify-and-treat model toward dynamic monitoring.25PubMed Central. GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care The idea is that two patients with identical spirometry, identical symptom scores, and identical exacerbation histories might still have different levels of ongoing disease activity, one stable and another smoldering with subclinical inflammation that will soon declare itself in a flare-up. Markers like persistently elevated eosinophils, rapid FEV1 decline between visits, and worsening CAT scores over time may help identify active disease before the next exacerbation arrives. This is still an evolving concept rather than a fully operational clinical tool, but it reflects the direction the field is heading: away from snapshots and toward longitudinal monitoring of trajectories.
Digital self-management platforms are beginning to feed into this approach. Trials of web- and app-based COPD management systems have shown improvements in CAT scores and inhaler technique, with greater gains seen in patients who used the tools more frequently.26PubMed Central. Digital healthcare in COPD management: a narrative review on the advantages, pitfalls, and need for further research If validated at scale, these platforms could provide the continuous symptom data needed to detect shifts in disease activity between clinic visits, potentially catching exacerbations before they require hospitalization. The infrastructure is still early-stage, but the GOLD framework’s recent emphasis on multi-dimensional, personalized assessment creates a natural home for it.